Abstract
Labetalol 1-5 mg/kg administered intravenously to normal subjects in the supine position produced an immediate mean fall in systolic (16%) and diastolic (25%) blood pressure with a concomitant increase in heart rate (12%). After graded exercise, intravenous labetalol inhibited increases in heart rate and blood pressure. Isoprenaline log dose response curves of increase in heart rate and reduction in diastolic pressure after intravenous labetalol shifted to the right in a parallel manner compared with pre-labetalol response curves suggestive of competitive antagonism at beta-adrenoceptor sites. Similarly, phenylephrine dose response curves of increase in systolic pressure before and after intravenous labetalol were suggestive of competitive antagonism at alpha-adrenoceptor sites. The ratio of relative potency alpha: beta adrenoceptor antagonism after intravenous labetalol was approximately 1:7, whereas in the same subjects after oral labetalol the ratio was approximately 1:3 as previously reported. Using the inhibition of isoprenaline tachycardia to estimate the potency of the beta-adrenoceptor antagonism of labetalol relative to that of propranolol the potency ratio was 1:6. However, using inhibition of Valsalva tachycardia as the index, the estimated ratio was approximately 1:3. Estimates of relative potency using inhibition of tilt tachycardia were complicated by the additional effects upon blood pressure after labetalol not seen after propranolol. Labetalol produced adrenoceptor blockade at both alpha and beta sites in man sufficient to explain its therapeutic antihypertensive effect.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aellig W. H. beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers. Br J Clin Pharmacol. 1976 Apr;3(2):251–257. doi: 10.1111/j.1365-2125.1976.tb00600.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Conway F. J., Fitzgerald J. D., McAinsh J., Rowlands D. J., Simpson W. T. Human pharmacokinetic and pharmacodynamic studies on the atenolo (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug. Br J Clin Pharmacol. 1976 Apr;3(2):267–272. doi: 10.1111/j.1365-2125.1976.tb00602.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Edwards R. C., Raftery E. B. Haemodynamic effects of long-term oral labetalol. Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):733–736. [PubMed] [Google Scholar]
- Farmer J. B., Kennedy I., Levy G. P., Marshall R. J. Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors. Br J Pharmacol. 1972 Aug;45(4):660–675. doi: 10.1111/j.1476-5381.1972.tb08125.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pearson R. M., Havard C. W. Intravenous labetalol in hypertensive patients treated with beta-adrenoreceptor-blocking drugs. Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):795–798. [PubMed] [Google Scholar]
- ROSE G. A., HOLLAND W. W., CROWLEY E. A. A SPHYGMOMANOMETER FOR EPIDEMIOLOGISTS. Lancet. 1964 Feb 8;1(7328):296–300. doi: 10.1016/s0140-6736(64)92408-0. [DOI] [PubMed] [Google Scholar]
- Richards D. A., Tuckman J., Prichard B. N. Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol. Br J Clin Pharmacol. 1976 Oct;3(5):849–855. doi: 10.1111/j.1365-2125.1976.tb00637.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rosei E. A., Trust P. M., Brown J. J., Lever A. F., Robertson J. I. Letter: Intravenous labetalol in severe hypertension. Lancet. 1975 Nov 29;2(7944):1093–1094. doi: 10.1016/s0140-6736(75)90470-5. [DOI] [PubMed] [Google Scholar]